mRNA Therapeutics - Thematic Intelligence
Summary
The field of mRNA therapeutics is in the early stages of clinical trial development.
The mRNA therapeutics landscape is promising with high projected sales in the coming years.
There are no current regulatory guidelines that dictate the approval and development process for mRNA therapeutics. They are instead regulated as gene therapies.
mRNA therapeutics must overcome barriers with delivery in order to be successful.
Key Highlights
There are currently no mRNA-based therapeutics that are not vaccines in any of the seven major pharmaceutical markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan).
There are five mRNA therapies in clinical trial development across various indications: three are in clinical trials for rare genetic diseases and two for different types of cancers; all five mRNA therapies are in Phase I/II development.
The mRNA therapeutics market is forecast to reach over $2 billion by 2028 globally.
OTX-2002 is projected to contribute most significantly to that revenue, generating $1.6 billion during 2028.
Scope
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook